Abstract

The gut microbiota influences the development and progression of metabolic diseases partly by metabolism of bile acids (BAs) and modified signaling through the farnesoid X receptor (FXR). In this study, we aimed to determine how the human gut microbiota metabolizes murine BAs and affects FXR signaling in colonized mice. We colonized germ-free mice with cecal content from a mouse donor or feces from a human donor and euthanized the mice after short-term (2 weeks) or long-term (15 weeks) colonization. We analyzed the gut microbiota and BA composition and expression of FXR target genes in ileum and liver. We found that cecal microbiota composition differed between mice colonized with mouse and human microbiota and was stable over time. Human and mouse microbiota reduced total BA levels similarly, but the humanized mice produced less secondary BAs. The human microbiota was able to reduce the levels of tauro-β-muricholic acid and induce expression of FXR target genes Fgf15 and Shp in ileum after long-term colonization. We show that a human microbiota can change BA composition and induce FXR signaling in colonized mice, but the levels of secondary BAs produced are lower than in mice colonized with a mouse microbiota.

Highlights

  • The gut microbiota influences the development and progression of metabolic diseases partly by metabolism of bile acids (BAs) and modified signaling through the farnesoid X receptor (FXR)

  • BA synthesis is regulated by FXR mainly via two downstream targets, fibroblast growth factor 19 (FGF19; in mice, FGF15) in ileum and small heterodimer partner (SHP) in Abbreviations: BA, bile acid; CA, cholic acid; CDCA, chenodeoxycholic acid; CONV-H, humanized; CONV-M, conventionalized; CONVR, conventionally raised; CYP7A1, cholesterol 7 -hydroxylase; CYP8B1, sterol 12- -hydroxylase; DCA, deoxycholic acid; FGF19/15, fibroblast growth factor 19/15; FXR, farnesoid X receptor; G, glycine; GF, germ free; HDCA, hyodeoxycholic acid; LCA, lithocholic acid; SHP, small heterodimer partner; T, taurine; / MCA, - and -muricholic acid; MCA, -muricholic acid

  • We have previously shown that differences in BA metabolism between germ-free (GF) and conventionally raised (CONV-R) mice are dependent on the FXR antagonist tauro- -muricholic acid (T MCA) [7]

Read more

Summary

Introduction

The gut microbiota influences the development and progression of metabolic diseases partly by metabolism of bile acids (BAs) and modified signaling through the farnesoid X receptor (FXR). We aimed to determine how the human gut microbiota metabolizes murine BAs and affects FXR signaling in colonized mice. BA synthesis is regulated by FXR mainly via two downstream targets, fibroblast growth factor 19 (FGF19; in mice, FGF15) in ileum and small heterodimer partner (SHP) in Abbreviations: BA, bile acid; CA, cholic acid; CDCA, chenodeoxycholic acid; CONV-H, humanized; CONV-M, conventionalized; CONVR, conventionally raised; CYP7A1, cholesterol 7 -hydroxylase; CYP8B1, sterol 12- -hydroxylase; DCA, deoxycholic acid; FGF19/15, fibroblast growth factor 19/15; FXR, farnesoid X receptor; G, glycine; GF, germ free; HDCA, hyodeoxycholic acid; LCA, lithocholic acid; SHP, small heterodimer partner; T, taurine; / MCA, - and -muricholic acid; MCA, -muricholic acid

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call